Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Dow
McKinsey
Merck
Harvard Business School
Mallinckrodt
AstraZeneca

Last Updated: January 24, 2020

DrugPatentWatch Database Preview

SIMPONI Drug Profile

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

Recent Clinical Trials for SIMPONI

Identify potential brand extensions & biosimilar entrants

SponsorPhase
Bio-Thera SolutionsPhase 1
Johnson & Johnson Private LimitedPhase 4
Juvenile Diabetes Research FoundationEarly Phase 1

See all SIMPONI clinical trials

Recent Litigation for SIMPONI

Identify key patents and potential future biosimilar entrants

District Court Litigation
Case NameDate
ABBVIE INC. v. SANDOZ INC.2018-08-10
Celgene Corporation v. Aurobindo Pharma Limited2018-07-06
CELGENE CORPORATION v. EMCURE PHARMACEUTICALS LTD.2018-06-28

See all SIMPONI litigation

Pharmacology for SIMPONI

Patent Text Search: US Patents for SIMPONI

These patents were identified by searching patent claims

Supplementary Protection Certificates for SIMPONI

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2017/056 Ireland   Start Trial PRODUCT NAME: SARILUMAB; REGISTRATION NO/DATE: EU/1/17/1196 20170623
CR 2017 00061 Denmark   Start Trial PRODUCT NAME: SARILUMAB; REG. NO/DATE: EU/1/17/1196/001-8 20170627
17C1057 France   Start Trial PRODUCT NAME: SARILUMAB; REGISTRATION NO/DATE: EU/1/17/1196 20170627
PA2017038 Lithuania   Start Trial PRODUCT NAME: SARILUMABAS; REGISTRATION NO/DATE: EU/1/17/1196 20170623
2017C/054 Belgium   Start Trial PRODUCT NAME: KEVZARA - SARILUMAB; AUTHORISATION NUMBER AND DATE: EU/1/17/1196 20170627
C201730049 Spain   Start Trial PRODUCT NAME: SARILUMAB; NATIONAL AUTHORISATION NUMBER: EU/1/17/1196; DATE OF AUTHORISATION: 20170623; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/17/1196; DATE OF FIRST AUTHORISATION IN EEA: 20170623
PA2017038,C2041177 Lithuania   Start Trial PRODUCT NAME: SARILUMABAS; REGISTRATION NO/DATE: EU/1/17/1196 20170623
>Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Baxter
AstraZeneca
McKesson
Medtronic
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.